These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 4262400

  • 1. Serotonergic mechanisms in Parkinson's disease.
    Chase TN.
    Arch Neurol; 1972 Oct; 27(4):354-6. PubMed ID: 4262400
    [No Abstract] [Full Text] [Related]

  • 2. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B, Roos BE.
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract] [Full Text] [Related]

  • 3. Parkinson's disease. Modification by 5-hydroxytryptophan.
    Chase TN, Ng LK, Watanabe AM.
    Neurology; 1972 May; 22(5):479-84. PubMed ID: 4563493
    [No Abstract] [Full Text] [Related]

  • 4. Central monoamine metabolism in Parkinson's disease.
    Chase TN, Ng LK.
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract] [Full Text] [Related]

  • 5. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J, Sharpe D, Curzon G.
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract] [Full Text] [Related]

  • 6. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH, Bowers MB.
    Experientia; 1970 May; 26(2):161-3. PubMed ID: 5308739
    [No Abstract] [Full Text] [Related]

  • 7. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W, Danielczyk W, Neumayer E, Riederer P.
    J Neural Transm; 1972 May; 33(2):163-78. PubMed ID: 4643007
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA, Dowson JH, Ahmed R, Chow R, Gillingham FJ.
    Confin Neurol; 1972 May; 34(1):143-8. PubMed ID: 5084388
    [No Abstract] [Full Text] [Related]

  • 9. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
    Rinne UK, Sonninen V.
    Neurology; 1972 Jan; 22(1):62-7. PubMed ID: 4550499
    [No Abstract] [Full Text] [Related]

  • 10. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.
    Johansson B, Roos BE.
    Life Sci; 1967 Jul 01; 6(13):1449-54. PubMed ID: 6035772
    [No Abstract] [Full Text] [Related]

  • 11. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C, Agnoli A, Jori A, Dolfini E.
    Z Neurol; 1973 Apr 02; 204(2):149-54. PubMed ID: 4121468
    [No Abstract] [Full Text] [Related]

  • 12. Clinical effects of para-chlorophenylalanine in Parkinson's disease.
    Van Woert MH, Ambani LM, Levine RJ.
    Dis Nerv Syst; 1972 Dec 02; 33(12):777-80. PubMed ID: 4272666
    [No Abstract] [Full Text] [Related]

  • 13. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN, Watanabe AM.
    Neurology; 1972 Apr 02; 22(4):384-92. PubMed ID: 5062828
    [No Abstract] [Full Text] [Related]

  • 14. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP, Korf J, Van Praag HM, Schut T.
    Nat New Biol; 1972 Apr 19; 236(68):208-9. PubMed ID: 4553111
    [No Abstract] [Full Text] [Related]

  • 15. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1973 Apr 19; 9(6):349-62. PubMed ID: 4712542
    [No Abstract] [Full Text] [Related]

  • 16. Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
    Mendlewicz J, Vanderheyden JE, Noel G.
    Adv Exp Med Biol; 1981 Apr 19; 133():753-67. PubMed ID: 6172024
    [Abstract] [Full Text] [Related]

  • 17. The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases.
    Papeschi R, Molina-Negro P, Sourkes TL, Erba G.
    Neurology; 1972 Nov 19; 22(11):1151-9. PubMed ID: 4263829
    [No Abstract] [Full Text] [Related]

  • 18. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH, Bowers MB.
    Neurology; 1970 Apr 19; 20(4):377. PubMed ID: 5534981
    [No Abstract] [Full Text] [Related]

  • 19. Depression and Parkinson's disease: possible role of serotonergic mechanisms.
    Kostić VS, Djuricić BM, Covicković-Sternić N, Bumbasirević L, Nikolić M, Mrsulja BB.
    J Neurol; 1987 Feb 19; 234(2):94-6. PubMed ID: 2435855
    [Abstract] [Full Text] [Related]

  • 20. Serotonergic mechanisms and extrapyramidal function in man.
    Chase TN.
    Adv Neurol; 1974 Feb 19; 5():31-9. PubMed ID: 4280243
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.